Who we are
Since 1876, Eli Lilly and Company (“Lilly”) has combined care with discovery to create medicines that transform the lives of people living with serious diseases. From its earliest days, Lilly has focused on bringing scientifically tested, high-quality medicines to patients, setting standards for modern pharmaceutical manufacturing and research.
Today, Lilly is a global biopharmaceutical company with a portfolio that includes therapies for diabetes, obesity, cardiovascular disease, neuroscience, immunology, and cancer. The company partners with healthcare professionals, patient organizations, and regulators worldwide to advance standards of care and expand access to innovative medicines.
Our purpose
Lilly’s stated purpose is to “create medicines that make life better for people around the world.” That purpose guides decisions across research, development, manufacturing, and responsible commercialization of medicines such as orforglipron.
For people living with chronic conditions like type 2 diabetes and obesity, this means a sustained commitment to advancing GLP‑1–based therapies, improving outcomes, and making treatments more convenient—such as exploring once‑daily oral options in addition to injectable medicines.
Heritage of innovation
Over nearly 150 years, Lilly has been associated with a number of firsts in modern medicine, including early large‑scale production of insulin, development of important antibiotics and treatments for mental health conditions, and the introduction of new classes of medicines for diabetes and obesity.
Orforglipron is part of this ongoing heritage—an investigational, once‑daily oral GLP‑1 receptor agonist being studied for weight management and type 2 diabetes. It builds on decades of Lilly experience in metabolic disease research and on extensive global clinical trial programs.
Focus on diabetes, obesity and cardiometabolic health
- Multiple clinical programs in type 2 diabetes and obesity, including the ACHIEVE and ATTAIN trials
- Research into how GLP‑1–based medicines can improve glycemic control and support sustained weight loss
- Ongoing studies evaluating long‑term cardiovascular and renal outcomes
Putting patients and safety first
Every investigational medicine, including orforglipron, is evaluated in carefully controlled clinical trials designed to understand safety, tolerability, and benefit–risk balance. Lilly works closely with regulators such as the U.S. Food and Drug Administration (FDA) and other global health authorities to review data before a medicine is approved for routine use.